Fairmount Funds Management LLC - 23 Oct 2025 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: VRDN
Reported as of: 23 Oct 2025
Net transaction value: +$9,999,990
SEC form: 4
Accepted by SEC: 27 Oct 2025, 16:30:38 UTC
Prior SEC filing: 09 Oct 2025
Next SEC filing: 17 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter Harwin, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 27 Oct 2025.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Oct 2025, 16:30.

Change

Previous filing in this sequence was filed on 09 Oct 2025.
Current net transaction value: +$9,999,990.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin, Managing Member of Fairmount Funds Management LLC
Signature date: 27 Oct 2025

CIK 0001830382

Fairmount Healthcare Fund II GP LLC

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II GP LLC
Signature date: 27 Oct 2025

CIK 0001769651

Fairmount Healthcare Fund II L.P.

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II L.P
Signature date: 27 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRDN transaction

Common Stock

Purchase

Transaction value: $9,999,990
Shares: +454,545
Change %: +13%
Price: $22.00
Shares after: 3,914,458
Date: 23 Oct 2025
Ownership: Fairmount Healthcare Fund II LP
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC remarks

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC.